Project Grant HT94252310031
Award Date
1/15/23
Completion Date
1/14/26
Dollars Obligated
$785K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
The Defense Health Agency awarded a $724,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Duke University. The grant, titled "Targeting Dormancy-Associated Immune Tolerance to Eliminate Residual Breast Cancer," will fund advanced biomedical research to transform healthcare for military service members, veterans, and the broader public. The research, to be conducted at Duke University's Office of Research Administration Division from March...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
The Defense Health Agency awarded $780,749 to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research into novel combination immune therapy regimens for metastatic breast cancer. The three-year project grant, beginning February 1, 2023, will fund the development of innovative medical solutions through basic, applied, and advanced biomedical research. Specifically, the awardee will investigate new...
The Defense Health Agency awarded a $524,664 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) through the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, which runs from December 1, 2024 to November 30, 2026, will fund research into the "Mechanisms of Irisin-Induced Cognitive Benefit in PD." DFCI, a prestigious non-profit cancer research center in Boston, will leverage its expertise in areas like oncology, immunology, and...
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
The Defense Health Agency awarded a $1,290,499.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on conducting research to develop innovative approaches to understanding, detecting, and treating ovarian cancer. DFCI, a prestigious non-profit cancer research center, will...
The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
The federal Project Grant award of $161,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Duke University to investigate breast cancer brain metastases. The research aims to integrate immunogenomic and phenotypic vulnerabilities to improve outcomes for this challenging condition. The award period runs from April 1, 2025 to March 31, 2026. This grant is part of the Defense Health Agency's strategic...